Midline lateralization thyroplasty was successfully performed on a patient with adductor spasmodic dysphonia. The thyroid cartilage was incised at the midline, and a 3 × 2-mm perforation was made at the anterior commissure to widen it. The perforation was closed with a free composite graft taken from the upper edge of the thyroid ala, and the incised thyroid cartilage edges were kept separated 4 mm apart with silicone wedges. A part of the sternohyoid muscle was rotated to seal any leak from the perforation. The postoperative course was uneventful. The voice has been restored to normal, and there is no sign of recurrence of the symptom so far, as of 1 year 5 months postoperative. Although a longer follow-up is needed, this case indicates that midline type II thyroplasty could be a useful treatment for adductor spasmodic dysphonia.
DedoHH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol1976; 85: 451–9.
2.
DedoHHIzdebskiK. Intermediate results of 306 recurrent laryngeal nerve sections for spastic dysphonia. Laryngoscope1983; 93: 9–16.
3.
DedoHHBehlauMS. Recurrent laryngeal nerve section for spastic dysphonia: 5- to 14-year preliminary results in the first 300 patients. Ann Otol Rhinol Laryngol1991; 100: 274–9.
4.
AronsonAEDeSantoLW. Adductor spastic dysphonia: three years after recurrent laryngeal nerve resection. Laryngoscope1983; 93: 1–8.
5.
FritzellBHammarbergBSchiratzkiHHaglundSKnutssonEMartenssonA. Long-term results of recurrent laryngeal nerve resection for adductor spasmodic dysphonia. J Voice1993; 7: 172–8.
6.
CarpenterRJHenley-CohnJLSnyderGG. Spastic dysphonia: treatment by selective section of the recurrent laryngeal nerve. Laryngoscope1979; 89: 2000–3.
7.
NettervilleJLStoneRERaineyCZealearDLOssoffRH. Recurrent laryngeal nerve avulsion for treatment of spastic dysphonia. Ann Otol Rhinol Laryngol1991; 100: 10–4.
8.
WeedDTJewettBSRaineyC. Long-term follow-up of recurrent laryngeal nerve avulsion for the treatment of spastic dysphonia. Ann Otol Rhinol Laryngol1996; 105: 592–601.
9.
MillerRHWoodsonGEJankovicJ. Botulinum toxin injection of the vocal fold for spasmodic dysphonia: a preliminary report. Arch Otolaryngol Head Neck Surg1987; 113: 603–5.
10.
BlitzerABrinMFFahnSLovelaceRE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope1988; 98: 193–7.
11.
BlitzerABrinMF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann Otol Rhinol Laryngol1991; 100: 85–9.
12.
BlitzerABrinMF. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin. J Voice1992; 6: 365–9.
MaloneyAPMorrisonMD. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia. J Otolaryngol1994; 23: 160–4.
15.
MurryTWoodsonGE. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy. J Voice1995; 9: 460–5.
16.
WongDLIrishJCAdamsSGDurkinLCHuntEJ. Laryngeal image analysis following botulinum toxin injections in spasmodic dysphonia. J Otolaryngol1995; 24: 64–8.
17.
FisherKVSchererRCGuoCGOwenAS. Longitudinal phonatory characteristics after botulinum toxin type A injection. J Speech Hear Res1996; 39: 968–80.
18.
InagiKFordCNBlessDMHeiseyD. Analysis of factors affecting botulinum toxin results in spasmodic dysphonia. J Voice1996; 10: 306–13.
19.
TewaryAK. Correlation between clinical response and injection quality in treatment of spasmodic dysphonia. J Laryngol Otol1996; 110: 551–3.
20.
BlitzerALovelaceREBrinMFFahnSFinkME. Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Otol Rhinol Laryngol1985; 94: 591–4.
21.
RavitsJMAronsonAEDeSantoLWDyckPJ. No morphometric abnormality of the recurrent laryngeal nerve in spastic dysphonia. Neurology1979; 29: 1376–82.
22.
SchaeferSDFinitzo-HieberTGerlingIJFreemanFJ. Brainstem conduction abnormalities in spasmodic dysphonia. Ann Otol Rhinol Laryngol1983; 92: 59–64.
23.
CarlsooBIzdebskiKDahlqvistADomeijSDedoHH. The recurrent laryngeal nerve in spastic dysphonia. A light and electron microscopic study. Acta Otolaryngol (Stockh) 1987; 103: 96–104.
24.
FinitzoT. Spasmodic dysphonia subsequent to head trauma. Arch Otolaryngol Head Neck Surg1987; 113: 1107–10.
25.
FinitzoTFreemanF. Spasmodic dysphonia, whether and where: results of seven years of research. J Speech Hear Res1989; 32: 541–55.
26.
DevousMDSrPoolKDFinitzoT. Evidence for cortical dysfunction in spasmodic dysphonia: regional cerebral blood flow and quantitative electrophysiology. Brain Lang1990; 39: 331–44.
27.
MartinelliPMontanariMIppolitiMMochiMSangiorgiSCapocasaM. Familial spasmodic dysphonia with low arylsulphatase A (ASA) level. Acta Neurol Scand1995; 91: 196–9.
28.
YamamotoTYamashitaM. Thalamo-olivary degeneration in a patient with laryngopharyngeal dystonia. J Neurol Neurosurg Psychiatry1995; 59: 438–41.
29.
RothCRGlazeLEGodingGSJrDavidWS. Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis. J Voice1996; 10: 362–7.
30.
LeeMSLeeSBKimWC. Spasmodic dysphonia associated with a left ventrolateral putaminal lesion. Neurology1996; 47: 827–8.
31.
Kiese-HimmelCKruseE. Psychological factors in spasmodic dysphonia. Laryngorhinootologie1996; 75: 397–402.
32.
NashEALudlowCL. Laryngeal muscle activity during speech breaks in adductor spasmodic dysphonia. Laryngoscope1996; 106: 484–9.
RoyNFordCNBlessDM. Muscle tension dysphonia and spasmodic dysphonia: the role of manual laryngeal tension reduction in diagnosis and management. Ann Otol Rhinol Laryngol1996; 105: 851–6.
35.
KumadaMKobayashiT. “Mora method” for objective evaluation of severity of spasmodic dysphonia [in Japanese]. Jpn J Logop Phoniatr1997; 38: 176–81.
36.
AronsonAE. Clinical voice disorders. An interdisciplinary approach. New York, NY: Brian C. Decker, 1980: 157–70.
37.
StoicheffM. The present status of adductor spastic dysphonia. J Otolaryngol1983; 12: 311–4.
38.
BrinMFBlitzerAStewartCFahnS. Treatment of spasmodic dysphonia (laryngeal dystonia) with local injections of botulinum toxin: review and technical aspects. In: BlitzerABrinMFSasakiC, eds. Neurologic disorders of the larynx. New York, NY: Thieme Medical Publishers, 1992: 214–28.
39.
MurryTWoodsonGE. Spasmodic dysphonia. In: BrownWSVinsonBPCraryMA, eds. Organic voice disorders: assessment and treatment. San Diego, Calif: Singular Publishing Group, 1996: 345–62.
40.
DeemsDASataloffRT. Spasmodic dysphonia. In: SataloffRT, ed. Professional voice: the science and art of clinical care. San Diego, Calif: Singular Publishing Group, 1997: 499–505.
41.
LudlowCLNauntonRFSedorySESchulzGMHallettM. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology1988; 38: 1220–5.
42.
ZwirnerPMurryTSwensonMWoodsonGE. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope1992; 102: 400–6.
43.
ZwirnerPMurryTWoodsonGE. Perceptual-acoustic relationships in spasmodic dysphonia. J Voice1993; 7: 165–71.
44.
StewartCFAllenELTureenPDiamondBEBlitzerABrinMF. Adductor spasmodic dysphonia: standard evaluation of symptoms and severity. J Voice1997; 11: 95–103.
45.
IsshikiN. Recent advances in phonosurgery. Folia Phoniatr1980; 32: 119–54.
